How Long Can You Take HRT? Why There Is No Fixed Stop Date

The short answer

The "five years and out" and "stop at 60" rules most people have heard are not current guidance. They are the residue of how large trial results in postmenopausal women were communicated in the early 2000s. As the NAMS 2022 statement sets out, research conducted largely in women well past the menopause transition was read as a verdict on all hormone therapy, at all ages, by all routes. Two decades of reanalysis narrowed that verdict considerably. What survived is that age at initiation and time since menopause matter enormously, that oral and transdermal estrogen carry different clotting and stroke profiles, and that the risk signal that drove the alarm belonged to a specific combined oral regimen used in older women — not to hormone therapy as a category.

Duration questions also split by what the therapy is for. Systemic hormone therapy for hot flashes, night sweats, and bone protection is one conversation. Low-dose vaginal estrogen for genitourinary syndrome of menopause is a genuinely different one: it is minimally absorbed, treats a condition that is progressive and does not remit on its own, and is typically continued for as long as symptoms would otherwise return. Applying a systemic-therapy stop rule to a vaginal estrogen cream is a category error that leaves women with treatable pain and urinary symptoms for no benefit.

Where the "five years" rule came from and why it no longer stands

The "lowest dose for the shortest time" rule of thumb dates to how landmark trial results were communicated in the early 2000s. The NAMS 2022 position statement describes that research as having enrolled women who were, on average, well past the menopause transition, with the combined arm using oral conjugated estrogens together with a synthetic progestin. A result obtained in that specific population, with that specific oral regimen, was generalized into a warning about hormone therapy as a whole — and a generation of clinicians absorbed the practical instruction to get women off it by their early sixties.

What changed was not the underlying data but the resolution at which it was read. NAMS 2022 sets out age-stratified findings showing that absolute risks differ substantially between women who start therapy near the onset of menopause and women who start a decade or more later. It distinguishes the estrogen-alone data — from women who had had a hysterectomy — which did not reproduce the breast cancer signal seen with combined therapy. And it notes observational evidence that transdermal delivery, little used in those older trials, carries a different venous thrombosis and stroke profile than oral estrogen. Each of these distinctions matters for a duration decision, and none of them are captured by a blanket five-year limit.

The NAMS 2022 position statement reflects that shift directly: it frames hormone therapy decisions as individualized and periodically reassessed, and it states that arbitrary limits should not be placed on duration of use. ACOG's patient guidance on the menopause years likewise describes hormone therapy as a decision made with a clinician based on symptoms, health history, and personal risk, rather than as a treatment with a preset endpoint.

What NAMS 2022 actually says about duration

Three positions in the 2022 statement do most of the work for someone asking how long they can stay on therapy. First, that hormone therapy should not be discontinued solely because a woman reaches age 65. Second, that arbitrary duration limits are not supported and that continuation beyond age 65 can be appropriate for persistent vasomotor symptoms, quality-of-life considerations, or prevention of osteoporosis when the woman has been counseled on risks and benefits. Third, that any longer-term use should be accompanied by ongoing review of the indication, the dose, and the route.

This is a meaningfully different framing from "the shortest duration possible." It shifts the question from how much time has elapsed to whether the reason for taking it still applies and whether the risk profile has changed. A woman with vasomotor symptoms that reliably return within weeks of every attempted stop has a live indication. A woman whose symptoms have quietly resolved and who is continuing out of habit does not, and that is a reason to reconsider dose or discontinuation regardless of whether she has been on it for three years or twelve.

The statement also emphasizes lowest effective dose for longer-term use. In practice, extended therapy often means a step down in dose over time rather than a hard stop, with the dose set by whether symptoms stay controlled rather than by a schedule.

One caveat worth stating plainly: "no arbitrary limit" is not the same as "indefinite by default." The absence of a cutoff places the burden on an actual review conversation. If nobody is re-examining the decision, the missing stop date becomes drift rather than a choice.

Age at initiation matters more than years on therapy

The single most useful concept for duration decisions is the timing of initiation. NAMS 2022 describes a more favorable benefit-risk profile for women who begin systemic hormone therapy before age 60 or within 10 years of their final menstrual period, particularly for bothersome vasomotor symptoms. Women who begin outside that window face a less favorable balance, largely because underlying cardiovascular and cerebrovascular risk rises with age and with years of estrogen deficiency.

This has a counterintuitive implication that is worth stating directly. Continuing therapy started at 51 into your early sixties is not the same proposition as starting therapy fresh at 64. The first is a continuation within a risk trajectory that was established early; the second introduces exogenous estrogen to a vascular system that has aged without it. Guidance that treats these as identical — the "everyone off at 60" rule — gets both cases wrong, discouraging reasonable continuation while implying that late initiation is equally routine.

Practically, this means the periodic review question for a long-term user is not "has it been too long?" but "if I were making this decision for the first time today, at my current age and with my current risk factors, would I start?" If the answer is yes, continuing is defensible. If the answer is no because of a new risk factor — a cardiovascular event, a thrombosis, a new breast cancer diagnosis — that new factor, not the elapsed time, is what should drive the change.

Route changes the risk math, and it changes it more the longer you continue

Oral estrogen passes through the liver before reaching systemic circulation, and that first-pass metabolism increases the production of clotting factors and other hepatic proteins. Transdermal estradiol — patch, gel, or spray — is absorbed through the skin and avoids that first pass. NAMS 2022 notes that observational evidence suggests transdermal therapy is associated with lower risk of venous thromboembolism and stroke than oral therapy, and this is why route is frequently the first thing adjusted when a woman wants to continue but her risk profile has shifted.

For someone weighing long-term continuation, this creates a real option that is not "stay on the same thing or stop." A woman on oral estradiol who develops obesity, migraine with aura, or a family history of clotting may be able to continue therapy on a transdermal preparation rather than discontinue. Similarly, a woman whose only remaining bothersome symptom is vaginal dryness and painful sex may be better served by switching from systemic therapy to low-dose vaginal estrogen than by extending systemic dosing she no longer needs for hot flashes.

Route also shapes what is realistic at the dose level. Transdermal products come in a range of patch strengths, and gels and sprays are dosed in adjustable increments, which makes the gradual step-down approach discussed below more practicable than it is with fixed-dose oral tablets. Patches should be used as supplied — ask your clinician which lower strength to move to rather than altering a patch yourself.

Whether you need a progestogen changes the long-term calculation

If you have a uterus and take systemic estrogen, you need a progestogen to protect the endometrium from unopposed estrogen stimulation. That is not optional and it is not dose-flexible in the way estrogen is. But it does mean that the long-term risk conversation for a woman with a uterus is structurally different from the conversation for a woman who has had a hysterectomy.

The breast cancer signal that drove most of the alarm about hormone therapy was observed with combined estrogen-progestogen therapy and, as NAMS 2022 describes, became apparent with continued use over years rather than immediately. The estrogen-alone data, from women who had had a hysterectomy, did not show that increase. NAMS 2022 characterizes the absolute risk attributable to combined therapy as rare in individual terms, but it is a real consideration that grows in weight with duration, and it is the most legitimate reason for a woman on combined therapy to revisit the question periodically rather than treating continuation as automatic.

The type of progestogen is part of that conversation. Micronized progesterone and synthetic progestins are not interchangeable in their metabolic and possibly breast effects, and a woman continuing combined therapy long term is entitled to ask whether her specific progestogen is the one best suited to extended use.

For women without a uterus, the absence of a progestogen removes the component most associated with the breast signal. This does not make estrogen alone risk-free — stroke and venous thrombosis considerations persist, and are route-dependent — but it does mean that extended use is a materially easier decision than it is for combined therapy.

Early menopause and primary ovarian insufficiency are the opposite case

For women who reach menopause early — spontaneously, or through surgical removal of the ovaries, chemotherapy, or radiation — the duration question inverts. NAMS 2022 supports continuing hormone therapy at least until the average age of natural menopause, which ACOG's patient guidance places around the early fifties, because these women are otherwise facing decades of estrogen deficiency that women with typical-timing menopause never experience.

The reasoning is straightforward: the concern about hormone therapy is about adding estrogen beyond the body's natural exposure window, and a woman whose ovaries stopped at 38 is not in that situation. She is replacing what her peers still have. Bone loss, cardiovascular risk, and genitourinary changes all accumulate over that gap, and hormone therapy in this population is more accurately described as replacement than as an added intervention.

Practically, a woman with primary ovarian insufficiency who is told at 44 that she has "been on it long enough" is receiving advice built for a different population. The clock in her case does not usefully start counting until she reaches the age at which menopause would have occurred naturally — and at that point, the standard duration conversation begins, from a normal starting position rather than from years of accumulated use.

Vaginal estrogen for GSM is a separate question with a different answer

Genitourinary syndrome of menopause — vaginal dryness, burning, painful intercourse, urinary urgency, recurrent urinary tract infections — differs from hot flashes in one important respect: it does not resolve on its own. Vasomotor symptoms typically diminish over years for most women. Genitourinary tissue changes are progressive and persist indefinitely without treatment. The 2020 NAMS position statement on genitourinary syndrome of menopause reflects this by treating low-dose vaginal estrogen as therapy to be continued as long as it is needed, rather than as a course with a natural endpoint.

Low-dose vaginal preparations — creams, tablets, inserts, and rings at the recommended doses — produce minimal systemic absorption. NAMS 2020 indicates that a progestogen is generally not required for endometrial protection with low-dose vaginal estrogen in women with an intact uterus, and that routine endometrial surveillance is not indicated in the absence of bleeding. That combination removes most of the considerations that drive duration limits on systemic therapy.

Symptoms return when treatment stops, because the underlying tissue change returns. This is the practical answer to "how long do I need this?": for as long as you want the symptoms treated. Many women use it indefinitely, at maintenance frequency rather than the initial loading schedule.

One rule remains absolute regardless of dose or route: any vaginal bleeding after menopause requires evaluation, even in a woman on low-dose vaginal estrogen. ACOG is explicit that postmenopausal bleeding should never be assumed to be a harmless side effect of therapy.

What actually happens when you stop

Discontinuation has three separable consequences, and conflating them is the most common source of confusion. Symptoms, bone, and genitourinary tissue all respond differently, on different timeframes, and a stopping plan should address each one that applies to you.

Vasomotor symptoms return in a substantial proportion of women who stop, and the return can occur within weeks. Whether they return depends heavily on where a woman is in her own natural symptom trajectory — a woman stopping at 65 who has been on therapy since 51 may find her underlying symptoms have subsided; a woman stopping at 55 after four years often finds they have not.

Bone protection ends with the therapy. Hormone therapy is effective at preserving bone mineral density and reducing fracture risk while it is being taken, but bone density declines after discontinuation and the fracture protection dissipates. This is the consequence that women most often fail to plan for, because it is silent. If bone protection was part of the reason for continuing, stopping should be accompanied by a bone density assessment and a discussion of whether another agent is warranted.

Genitourinary symptoms return, and return reliably, because the tissue change is progressive. This is why a woman stopping systemic therapy is often continued on low-dose vaginal estrogen — the two decisions are separable and should be made separately.

Tapering versus stopping abruptly

There is no strong evidence that gradual tapering prevents symptom recurrence in the long run. Whether symptoms come back appears to depend more on where a woman is in her own natural menopausal trajectory than on how quickly she came off. Both approaches are reasonable, and NAMS 2022 does not endorse one over the other as a general rule.

What tapering does offer is a diagnostic advantage. Stepping down in increments — reducing the estradiol dose, or moving to a lower patch strength, over a period of months — makes it possible to identify the lowest dose that still controls symptoms. Some women discover during a taper that they are comfortable at a lower dose than they had been taking, which converts a stop-or-continue question into a dose question and is often the better outcome. Others find symptoms return sharply at a specific step, which is itself useful information about whether stopping is realistic right now.

A taper is easier with transdermal preparations, where a range of patch strengths and adjustable gel doses is available, than with fixed-dose oral tablets. It also works better on a slow schedule — reductions spaced over weeks to months rather than days — because vasomotor symptoms can lag a dose change.

A stopping attempt is not a commitment. If symptoms return at a level that materially affects sleep, work, or quality of life, resuming therapy is a legitimate outcome, not a failure. The practical framing worth bringing to the appointment is: what would we do if I stop and the symptoms come back? Agreeing on that answer in advance prevents a rough three months from becoming a permanent decision made by inertia.

How to structure the periodic review conversation

"No arbitrary limit" only works as guidance if someone is actually reviewing the decision. An annual review does not need to be long, but it should cover a defined set of items rather than defaulting to a refill.

The core question is whether the original indication still applies. If it was vasomotor symptoms, are they still present when you miss doses? If it was bone protection, what does your current fracture risk assessment look like? If it was early menopause, have you reached the age at which the standard duration conversation should begin?

The second question is whether anything in your risk profile has changed since the last review — new cardiovascular disease, a thrombotic event, a new breast cancer diagnosis or a first-degree family history, uncontrolled hypertension, new migraine with aura, or a significant change in weight or smoking status. Any of these may change the recommendation about route, dose, or continuation, and they, rather than duration, are what should trigger a change.

The third is whether the dose and route are still the right ones. Doses that were appropriate for severe symptoms at 52 are frequently higher than needed at 62. Oral therapy that was fine at initiation may warrant a switch to transdermal as vascular risk factors accumulate. And a woman whose remaining symptoms are entirely genitourinary may be better served by moving from systemic to vaginal therapy.

Bleeding on hormone therapy puts the duration question on hold

Any postmenopausal bleeding requires evaluation. ACOG's patient guidance on perimenopausal and postmenopausal bleeding is direct about this: bleeding after menopause is not normal and should be reported, because it can be the first sign of endometrial hyperplasia or cancer. On hormone therapy, some bleeding patterns are expected — scheduled withdrawal bleeding on a cyclic regimen, or breakthrough bleeding in the early months of a continuous combined regimen. Bleeding that is unscheduled, that starts after a period of no bleeding, or that persists beyond the initial adjustment period is not in that category.

ACOG's committee opinion on transvaginal ultrasonography describes its role in evaluating the endometrium in women with postmenopausal bleeding, with an endometrial thickness of 4 mm or less carrying a high negative predictive value for endometrial cancer, and thicker measurements or persistent bleeding prompting tissue sampling. The important point for a woman on hormone therapy is that this pathway exists and is fast — the evaluation is not a reason to delay reporting the bleeding.

An incidentally thickened endometrium found on imaging done for another reason, in a woman with no bleeding, is a different situation. The 2024 SOGC guideline on asymptomatic endometrial thickening in postmenopausal women addresses exactly this scenario and distinguishes it from the workup indicated for bleeding. Bring the report to your clinician rather than assuming either that it is nothing or that it is serious.

Where this intersects with duration: bleeding is a reason to evaluate, not automatically a reason to stop hormone therapy. Sometimes the evaluation leads to a change in the progestogen regimen rather than discontinuation. But the evaluation comes first, and it should not wait for a scheduled review.

Continuing past 65: when it is reasonable and when it is not

NAMS 2022 is explicit that there are no data supporting routine discontinuation at 65 and that therapy can appropriately continue beyond that age for persistent vasomotor symptoms, quality of life, or prevention of osteoporosis, with appropriate counseling and ongoing evaluation. The lowest effective dose applies with more force at this stage, and route review — particularly the case for transdermal over oral — becomes more relevant as background vascular risk rises.

Continuation past 65 is most defensible when therapy was started near the menopause transition and has been continuous, when symptoms reliably return on withdrawal, when the woman has been counseled on the risk picture, and when a periodic review is actually happening. Bone protection can also justify continuation in a woman at meaningful fracture risk, though NAMS notes that other agents specifically indicated for osteoporosis should be considered as part of that discussion.

It is less defensible when nobody can articulate what the therapy is currently treating, when the dose has never been reviewed, when the route no longer matches the risk profile, or when significant new contraindications have appeared and gone unaddressed. In those cases the problem is not the number 65 — it is that no decision is being made.

Starting systemic hormone therapy for the first time at an advanced age is a distinct question with a less favorable balance, driven by the timing considerations described above. Anyone in that position should expect a more detailed discussion of alternatives, and should not read "no arbitrary limit on duration" as a green light for late initiation.

Putting it together: how the decision is actually made

The functional version of "how long can I take HRT" is a short sequence of questions. Does the indication still exist? Has the risk profile changed? Is this the lowest dose and the best route for me now? What is the plan for bone if I stop? And are genitourinary symptoms being handled separately from the systemic decision? Answer those five, annually, and the elapsed-years question mostly answers itself.

What should not happen is a stop driven by a number — a birthday, an anniversary of the first prescription, or a rule a clinician absorbed two decades ago and has not revisited. If you are told to stop and the reason given is duration or age alone, it is reasonable to ask what specifically about your risk profile has changed, and to ask whether a dose reduction or a route change would address the concern instead of discontinuation.

If you want to change providers or compare options for menopause care, compare providers on what they actually offer: whether transdermal estradiol is available and not just oral, whether low-dose vaginal estrogen can be prescribed independently of systemic therapy, whether progestogen type is discussed rather than defaulted, and whether an annual review is built into the service rather than an automatic refill. Those features determine whether the duration question gets revisited properly or simply never gets asked.

Questions to ask your clinician

Bring these to your appointment — they turn a vague visit into a decision.

• If I were 62 and coming to you for the first time today with my current risk factors, would you start me on this therapy? If yes, what would make continuing it different?
• Is there a specific change in my health that makes you want me to stop, or is the recommendation based on how long I've been taking it?
• Would switching from oral to transdermal estradiol address the risk you're concerned about, instead of stopping altogether?
• If we step my dose down rather than stop, what schedule would you use, and how long should I wait at each step before deciding whether it's working?
• If I stop and the hot flashes come back badly, what's the plan — can I restart, and how quickly?
• Before I stop, should I have a bone density scan, and would I need a different medication to protect my bones afterward?
• Can I keep using low-dose vaginal estrogen for dryness even if I come off systemic hormone therapy?

Frequently asked questions

Is there a maximum number of years I can take HRT?

No. The 2022 NAMS position statement says arbitrary limits should not be placed on duration of hormone therapy, and that there are no data supporting routine discontinuation at age 65. Continuation is decided by whether the indication still applies and whether the risk profile has changed, with periodic review and the lowest effective dose for longer-term use.

Why did I hear I should stop HRT after five years?

That rule descends from how landmark trial findings were interpreted in the early 2000s. As the NAMS 2022 position statement describes, that research used a specific oral combined regimen in women who were, on average, well past the menopause transition, and the results were generalized to all hormone therapy at all ages by all routes. NAMS 2022 sets out the age-stratified picture, the different findings with estrogen alone, and the observational evidence on transdermal delivery, all of which narrow that conclusion. Current NAMS guidance no longer supports a fixed five-year rule.

Do I have to stop HRT when I turn 60 or 65?

No. NAMS 2022 states there are no data supporting routine discontinuation at 65 and that continuation can be appropriate for persistent vasomotor symptoms, quality of life, or osteoporosis prevention, provided the woman has been counseled and the therapy is reviewed periodically at the lowest effective dose. Age is a reason to review dose and route, not an automatic reason to stop.

Should I taper off HRT or stop abruptly?

There is no strong evidence that tapering prevents symptom recurrence over the long run — recurrence depends more on where you are in your own menopausal trajectory. Tapering does have a practical advantage: stepping down in increments often reveals the lowest dose that still controls symptoms, which can turn a stop-or-continue question into a dose question. Tapering is easier with transdermal preparations than with fixed-dose tablets.

What happens to my bones if I stop HRT?

Bone mineral density declines after discontinuation and the fracture protection provided by hormone therapy dissipates. Because bone loss is silent, this is the consequence women most often fail to plan for. If bone protection was part of your reason for taking hormone therapy, stopping should be accompanied by a bone density assessment and a discussion of whether an agent specifically indicated for osteoporosis is warranted.

How long can I use vaginal estrogen for dryness and painful sex?

Typically for as long as you need it. The 2020 NAMS position statement on genitourinary syndrome of menopause treats low-dose vaginal estrogen as therapy continued as long as symptoms would otherwise return, because the underlying tissue change is progressive rather than self-limiting. At recommended low doses, systemic absorption is minimal, a progestogen is generally not required for endometrial protection, and routine endometrial surveillance is not indicated in the absence of bleeding.

Is transdermal estrogen safer than oral for long-term use?

NAMS 2022 notes that observational evidence suggests transdermal estradiol carries lower risk of venous thromboembolism and stroke than oral estrogen, because it bypasses first-pass liver metabolism and its effect on clotting factors. That difference becomes more relevant the longer therapy continues and as vascular risk factors accumulate, which is why a route switch is often the first adjustment considered when a woman wants to continue but her risk profile has shifted.

Does it matter that I had a hysterectomy?

Yes, substantially. Without a uterus you do not need a progestogen, and the breast cancer signal that drove most of the historical concern was associated with combined estrogen-progestogen therapy rather than estrogen alone. That makes extended use of estrogen alone a materially easier long-term decision — though stroke and thrombosis considerations still apply and remain route-dependent.

I have primary ovarian insufficiency. Do the same duration rules apply?

No. NAMS 2022 supports continuing hormone therapy in women with early or premature menopause at least until the average age of natural menopause. In this situation hormone therapy replaces what peers still produce rather than adding estrogen beyond a natural window. Standard duration questions begin from that age, not from the year you started.

I bled after months of no bleeding on HRT. Is that just a side effect?

Treat it as something to report promptly, not as an expected side effect, and do not wait for your next scheduled review. ACOG is clear that bleeding after menopause is not normal and needs evaluation, because it can be the first sign of endometrial hyperplasia or cancer. ACOG's committee opinion describes transvaginal ultrasonography's role in that evaluation, with an endometrial thickness of 4 mm or less carrying a high negative predictive value and thicker measurements or persistent bleeding prompting tissue sampling.

Primary sources

1. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 2022. PMID 35797481.
2. The 2020 genitourinary syndrome of menopause position statement of NAMS. Menopause, 2020. PMID 32852449.
3. ACOG: The Menopause Years (patient FAQ).
4. ACOG: Perimenopausal Bleeding and Bleeding After Menopause (patient FAQ).
5. ACOG Committee Opinion: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding.
6. Guideline No. 451: Asymptomatic Endometrial Thickening in Postmenopausal Women. J Obstet Gynaecol Can, 2024. PMID 38901794.